Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
NT$ 15.1
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
InnoPharmax Inc., a specialty pharmaceutical company, develops and commercializes products for the treatment of oncology and other specialties in Taiwan. The company's core products include N11005, a prandial oral insulin; and GemOral. It also offers Imipenem and Cilastatin solution for the treatment of infections caused by susceptible organisms, such as lower respiratory tract, skin and...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Data is available to registered users only
Buy
Sell